Combined effects of the two reciprocal t(4;11) fusion proteins MLL·AF4 and AF4·MLL confer resistance to apoptosis, cell cycling capacity and growth transformation

Oncogene

Volumn 26, Issue 23, 2007, Pages 3352-3363

  Gaussmann, A ^a   Wenger, T ^b,c   Eberle, I ^a   Bursen, A ^a   Bracharz, S ^a   Herr, I ^b   Dingermann, T ^a   Marschalek, R ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

Acute leukemia; AF4; MLL; Nanog; t(4; 11) fusion proteins

Indexed keywords

HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 FUSION PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN NANOG; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BMI1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CONTACT; CELL CYCLE; CELL FUNCTION; CELL GROWTH; CELL RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; LEUKEMIA; MOUSE; NONHUMAN; PHENOTYPE; PHYSIOLOGY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 4; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MICE; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 34249104594     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210125     Document Type: Article

References (38)

1. Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W et al. (2004). Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 64: 4736-4743.
2. Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Edén P et al. (2005). Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci USA 102: 19069-19074.
3. Ayton PM, Cleary ML. (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298-2307.
4. Booth HA, Holland PW. (2004). Eleven daughters of NANOG. Genomics 84: 229-238.
5. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
6. Bursen A, Moritz S, Gaussmann A, Moritz S, Dingermann T, Marschalek R. (2004). Interaction of AF4 wildtype and AF4·MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology? Oncogene 23: 6237-6249.
7. Caslini C, Serna A, Rossi V, Introna M, Biondi A. (2004). Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. Leukemia 18: 1064-1071.
8. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S et al. (2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655.
9. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. (2006). A murine Mll-AF4 knockin model results in lymphoid and myeloid deregulation and hematological malignancy. Blood March 21 (e-pub ahead of print).
10. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. (1999). Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94: 1209-1217.
11. Downing JR, Head DR, Raimondi SC, Carroll AJ, Curcio-Brint AM, Motroni TA et al. (1994). The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 83: 330-335.
12. Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ. (1995). ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85: 3250-3256.
13. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U et al. (1994). The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 86: 275-283.
14. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E et al. (2005). Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 102: 8603-8608.
15. Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE et al. (2005). Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 47: 48-56.
16. Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C et al. (2006). Dissecting self-renewal in stem cells with RNA interference. Nature 442: 533-538.
17. Janssen JW, Ludwig WD, Borkhardt A, Spadinger U, Rieder H, Fonatsch C et al. (1994). Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 84: 3835-3842.
18. Jordan CT, Guzman ML, Noble M. (2006). Cancer stem cells. N Engl J Med 355: 1253-1261.
19. Kersey JH, Wang D, Oberto M. (1998). Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12: 1561-1564.
20. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I et al. (1987). Growth factor requirements of childhood acute leukemia: establishment of GM-CSFdependent cell lines. Blood 70: 192-199.
21. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. (2006). Control of developmental regulators by polycomb in human embryonic stem cells. Cell 21: 301-313 (doi 10.1016/j.cell.2006. 02.043).
22. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X et al. (2006). The Oct4 and Nanog transcription networkregulates pluripotency in mouse embryonic stem cells. Nat Genet 5: March (e-pub ahead of print).
23. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN et al. (2006). A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 25: 3093-3103.
24. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K et al. (2003). The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642.
25. Mitterbauer-Hohendanner G, Mannhalter C. (2004). The biological and clinical significance of MLL abnormalities in haematological malignancies. Eur J Clin Invest 34: 12-24.
26. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. (1994). 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12: 909-915.
27. Reichel M, Gillert E, Angermüller S, Hensel JP, Heidel F, Lode M et al. (2001). Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene 20: 2900-2907.
28. Skotheim RI, Lind GE, Monni O, Nesland JM, Abeler VM, Fossa SD et al. (2005). Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 65: 5588-5598.
29. So ECW, Wong P, Lin M, Cleary ML. (2004). Disease models and transformation mechanisms mediated by MLL-AF4 family oncoproteins in human leukemia. ASH Abst 467.
30. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. (1985). Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65: 21-31.
31. Strasser A, Harris AW, Bath ML, Cory S. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
32. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S et al. (2006). Proteolysis of MLL family proteins is essential for Taspase1-orchestrated cell cycle progression. Genes Dev 29: 2397-2409.
33. Taranger CK, Noer A, Sorensen AL, Hakelien AM, Boquest AC, Collas P. (2005). Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 16: 5719-5735.
34. Terranova R, Agherbi H, Boned A, Meresse S, Djabali M. (2006). Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci USA 103: 6629-6634.
35. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O. (2005). Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106: 3559-3566.
36. Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA et al. (2005). The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci USA 102: 14028-14033.
37. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. (1995). Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378: 505-508.
38. Zhang J, Wang X, Li M, Han J, Chen B, Wang B et al. (2006). NANOGP8 is a retrogene expressed in cancers. FEBS J 273: 1723-1730.